Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404)

Neoplasia

Volumn 11, Issue 8, 2009, Pages 793-803

  Wang, Liang Chuan S ^a   Thomsen, Lotte ^a   Sutherland, Rachel ^a   Reddy, Charu B ^a   Tijono, Sofian M ^a   Chen, Chun Jen J ^b   Angel, Catherine E ^b   Dunbar, P Rod ^b,c   Ching, Lai Ming ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ALPHA3 INTEGRIN; CD11B ANTIGEN; CD45RB ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CELL INFILTRATION; CELL STRUCTURE; CELL SUBPOPULATION; COLON TUMOR; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; LEUKOCYTE; LEUKOCYTE COUNT; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR VOLUME;

EID: 67650485823     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09506     Document Type: Article

References (34)

1. Rewcastle GW, Atwell GJ, Li ZA, Baguley BC, and Denny WA (1991). Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. JMed Chem 34, 217-222.
2. Plowman J, Narayanan VL, Dykes D, Szarvasi E, Briet P, Yoder OC, and Paull KD (1986). Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep 70, 631-635.
3. Baguley BC, Calveley SB, Crowe KK, Fray LM, O'Rourke SA, and Smith GP (1989). Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice. Eur J Cancer Clin Oncol 25, 263-269.
4. Ching LM, Goldsmith D, Joseph WR, Korner H, Sedgwick JD, and Baguley BC (1999). Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 59, 3304-3307.
5. Cao Z, Joseph WR, Browne WL, Mountjoy KG, Palmer BD, Baguley BC, and Ching LM (1999). Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 80, 716-723.
6. Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, and Ching LM (1999). Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 59, 633-638.
7. Zhao L, Ching LM, Kestell P, and Baguley BC (2002). The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 87, 465-470.
8. Perera PY, Barber SA, Ching LM, and Vogel SN (1994). Activation of LPS-inducible genes by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid in primary murine macrophages. Dissection of signaling pathways leading to gene induction and tyrosine phosphorylation. J Immunol 153, 4684-4693.
9. Wang L-CS, Woon S-T, Baguley BC, and Ching L-M (2006). Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitors. Oncol Res 16, 1-14.
10. Cao Z, Baguley BC, and Ching LM (2001). Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res 61, 1517-1521.
11. + T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res 65, 11752-11761.
12. Wallace A, LaRosa DF, Kapoor V, Jing S, Cheng G, Jassar A, Blouin A, Ching L-M, and Albelda SM (2007). The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes. Cancer Res 67, 7011-7019.
13. Lloyd CM, Phillips ARJ, Cooper GJS, and Dunbar PR (2008). Three-colour fluorescence immunohistochemistry reveals the diversity of cells staining for macrophage markers in murine spleen and liver. J Immunol Methods 334, 70-81.
14. Angel CE, Chen CJ, Horlacher OC, John T, Browning J, MacGregor D, Cebon J, and Dunbar PR (2009). Distinctive localization of antigen presenting cells in human lymph nodes. Blood 113, 1257-1267.
15. Angel CE, George E, Brooks AE, Ostrovsky LL, Brown TL, and Dunbar PR (2006). Cutting edge: CD1a+ antigen-presenting cells in human dermis respond rapidly to CCR7 ligands. J Immunol 176, 5730-5734.
16. Wang LC, Reddy CB, Baguley BC, Kestell P, Sutherland R, and Ching LM (2004). Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites. Biochem Pharmacol 67, 937-945.
17. Lentsch AB and Ward PA (2000). Regulation of inflammatory vascular damage. J Pathol 190, 343-348.
18. Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, and Baguley BC (2002). Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 86, 1937-1942.
19. Zwi LJ, Baguley BC, Gavin JB, and Wilson WR (1994). Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res 6, 79-85.
20. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, and Wilson WR (1998). Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78, 439-445.
21. Parkins CS, Holder AL, Hill SA, Chaplin DJ, and Tozer GM (2000). Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer 83, 811-816.
22. Lui JJ, Ching L-M, Goldthorpe M, Sutherland R, Baguley BC, Kirker JA, and McKeage MJ (2007). Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours. Cancer Chemother Pharmacol 59, 661-669.
23. Schall TJ and Bacon KB (1994). Chemokines, leucocyte trafficking, and inflammation. Current Opinion Immunol 6, 865-873.
24. Pay S, Musabak U, Erdem H, Simsek I, Pekel A, Sengul A, and Dinc A (2005). Chimerical anti-TNF-alpha, infliximab, inhibits neutrophil chemotaxis and production of reactive oxygen species by blocking the priming effect of mononuclear cells on neutrophils. Immunopharmacol Immunotoxicol 27, 187-198.
25. Pang J-H, Cao Z, Joseph WR, Baguley BC, and Ching L-M (1998). Antitumor activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor. Eur J Cancer 34, 1282-1289.
26. Roberts ZJ, Ching L-M, and Vogel SN (2008). IFN-β-dependent inhibition of tumor growth by the vascular disrupting agent 5,6- dimethyxanthenone-4-acetic acid (DMXAA). J Inteferon Cytokine Res 28, 133-139.
27. Roberts ZJ, Goutagny N, Perera P-Y, Kato H, Kumar H, Kawai T, Akira S, Savan R, van Echo D, Fitzgerald KA, et al. (2007). The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J Exp Med 204, 1559-1569.
28. de Visser KE, Korets LV, and Coussens LM (2005). De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7, 411-423.
29. Roberts ZJ, Toshchakov V, Cuesta M, Thomas KE, Polumuri S, Rallabhandi P, Ching LM, and Vogel SN (2004). Utilization of known TLR signaling pathways in the activation of murine macrophages by the inflammatory anti-tumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). J Leukoc Biol Suppl 76, 32; [abstract 43].
30. Patel S, Parkin S, and Bibby MC (1997). The effect of 5,6-dimethylxanthenone-4-acetic acid on tumour necrosis factor production by human immune cells. Anticancer Res 17, 141-150.
31. Philpott M, Joseph WR, Crosier KE, Baguley BC, and Ching L-M (1997). Production of tumour necrosis factor-α by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4- acetic acid (NSC 640488). Br J Cancer 76, 1586-1591.
32. McKeage MJ, Fong P, Jeffrey M, Baguley BC, Kestell P, Ravic M, and Jameson MB (2006). 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 12, 1776-1784.
33. Jameson M, Thompson P, Baguley B, Evans B, Harvey V, Porter D, McCrystal M, and Kestell P (2000). Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Proc Am Soc Clin Oncol 19; [abstract 705].
34. Rustin GJS, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S, Bellenger K, Gumbrell L, Folkes L, and Halbert G (2003). 5,6-Dimethylxanthenone- 4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 88, 1160-1167.